First Turn Management LLC Sells 48,296 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

First Turn Management LLC trimmed its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 18.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 211,985 shares of the company's stock after selling 48,296 shares during the quarter. Vaxcyte makes up 3.8% of First Turn Management LLC's portfolio, making the stock its 5th biggest holding. First Turn Management LLC owned 0.19% of Vaxcyte worth $24,224,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. lifted its position in shares of Vaxcyte by 68.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 21,466 shares of the company's stock valued at $2,453,000 after acquiring an additional 8,685 shares in the last quarter. Harbor Capital Advisors Inc. lifted its position in Vaxcyte by 392.4% during the second quarter. Harbor Capital Advisors Inc. now owns 40,342 shares of the company's stock valued at $3,046,000 after buying an additional 32,149 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Vaxcyte by 18.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company's stock worth $216,966,000 after buying an additional 498,359 shares during the period. Russell Investments Group Ltd. acquired a new stake in shares of Vaxcyte in the first quarter worth $1,288,000. Finally, Tri Locum Partners LP purchased a new position in shares of Vaxcyte in the 2nd quarter valued at $8,559,000. Institutional investors and hedge funds own 96.78% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. BTIG Research boosted their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a "buy" rating in a research report on Tuesday, September 3rd. Jefferies Financial Group boosted their price objective on shares of Vaxcyte from $108.00 to $129.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. Needham & Company LLC reissued a "buy" rating and issued a $140.00 target price on shares of Vaxcyte in a report on Wednesday, November 6th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, Mizuho increased their target price on Vaxcyte from $113.00 to $163.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 10th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vaxcyte has a consensus rating of "Buy" and an average target price of $147.50.

Vaxcyte Stock Performance

Shares of NASDAQ:PCVX traded up $0.59 during trading on Tuesday, reaching $87.08. The company had a trading volume of 1,149,755 shares, compared to its average volume of 892,162. The firm has a market capitalization of $10.85 billion, a PE ratio of -18.80 and a beta of 1.01. Vaxcyte, Inc. has a twelve month low of $48.24 and a twelve month high of $121.06. The firm's fifty day moving average is $110.09 and its 200 day moving average is $88.98.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter last year, the business posted ($0.91) earnings per share. Equities analysts predict that Vaxcyte, Inc. will post -4.14 earnings per share for the current fiscal year.

Insider Activity at Vaxcyte

In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the firm's stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total transaction of $927,520.00. Following the transaction, the chief financial officer now directly owns 90,383 shares in the company, valued at $10,479,005.02. This trade represents a 8.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Grant Pickering sold 2,366 shares of the company's stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $103.89, for a total transaction of $245,803.74. Following the sale, the chief executive officer now directly owns 137,398 shares of the company's stock, valued at approximately $14,274,278.22. This represents a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 117,464 shares of company stock valued at $12,640,276. Company insiders own 3.10% of the company's stock.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.